You are here

New Drug Application for First Digital Medicine Under Review

Companies pursue regulatory filing for drug/device combo

The FDA accepted a drug/device product application combining aripiprazole (Abilify, Otsuka) with Proteus’ ingestible sensor in a single tablet, which will record ingestion and, with the patient’s consent, share the information with caregivers and health care professionals. The application marks the first time an FDA-approved medication has been submitted with a sensor within the drug dosage to measure adherence and response.

The tablet contains an ingestible sensor that communicates with a wearable sensor patch and a medical software app to measure adherence to treatment in adults with schizophrenia and in those with manic and mixed episodes associated with bipolar I disorder, and to measure  adjunctive therapy for major depressive disorder.

When aripiprazole with the embedded ingestible sensor is ingested, the sensor sends a signal to the wearable Proteus patch after it reaches the stomach. The patch records and time-stamps the information from the sensor in addition to collecting other patient metrics, including rest, body angle, and activity patterns. This information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and (only with their consent) to their physicians and/or caregivers. Patients view the information using a secure local software application on their mobile phone or device. Physicians and caregivers view the data using secure web portals.

Source: Otsuka, September 11, 2015

More Headlines

Synergistic Effects Seen When Combined With Cisplatin in Mice
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
For Locally Advanced or Metastatic Triple-Negative Type Only
41,000+ Medical Device Reports of Deaths, Serious Injuries, and Malfunctions in 7 Years
Purportedly Sterile Products Made in Unsanitary Conditions, Judge Says
Small-Molecule Drug Blocks Oxidative Stress Signals
MP-101 Has Potential to Drastically Alter Disease Progression